RapidAI

RapidAI (operating at rapidai.com) is an enterprise clinical AI platform engineered for healthcare providers seeking to accelerate diagnostic precision and streamline patient care. Founded in 2012 and headquartered in San Mateo, CA, RapidAI specializes in AI-driven medical imaging analysis, transforming how clinicians interpret critical scans like CT and MRI. Unlike traditional imaging tools that rely solely on human expertise, RapidAI’s platform integrates deep learning algorithms to detect conditions such as stroke, pulmonary embolism, and aortic dissection with high accuracy—often in real time. Under the hood, its proprietary AI models, trained on vast datasets, analyze imaging data to highlight abnormalities, generate actionable insights, and even suggest treatment pathways. This empowers radiologists and emergency responders to make faster, more confident decisions, reducing diagnostic delays and improving patient outcomes. Trusted by over 2,500 hospitals across 100+ countries, RapidAI has raised $100 million in funding, including a $75 million Series C round led by Vista Credit Partners and a $25 million Series B round from Lennertz & Co.